VAPOHYSTERO: Evaluation of a Hysteroscopic Method With Vaporization in the Hysteroscopic Treatment of Submucosal Uterine Fibroids

Sponsor
Assistance Publique Hopitaux De Marseille (Other)
Overall Status
Recruiting
CT.gov ID
NCT05078307
Collaborator
(none)
54
1
2
32
1.7

Study Details

Study Description

Brief Summary

Operative hysteroscopy (OH) is an endoscopic technique for the treatment of benign intrauterine lesions and in particular uterine fibroids. The limit of this technique is the duration of the operation which is correlated with the operative risks. Thus, when there is a large fibroid or several fibroids, this technique can sometimes not be used or require several sessions. Today there is a new technique of HO that theoretically allows a gain in operative time. There are few comparative studies showing a clinically interesting gain in operating time. The aim of this study is to compare the operative time between the classical HO technique by resection and the vaporization technique.

This is a randomized, single-center study. The study population corresponded to women aged over 18 years requiring operative hysteroscopy for fibroids. After obtaining informed consent, patients will be randomized into two groups: a vaporization hysteroscopy group and a resection hysteroscopy group. The primary endpoint will be operative time. The secondary endpoints will be intraoperative characteristics and complications (amount of distension fluid used, cervical injury, uterine perforation), immediate postoperative data (pain) and medium-term data (postoperative synechiae). The starting hypothesis is that the technique of hysteroscopy by vaporization would reduce the operative time by 30%. The number of subjects required per group will be 27 patients, or 54 patients in total over 24 months.

The expected results are a significant decrease in operative time with the vaporization hysteroscopy technique. This would be important because the reduction in operative time is associated with a reduction in complications of operative hysteroscopy and the possibility of treating larger fibroids with this technique.

Condition or Disease Intervention/Treatment Phase
  • Procedure: OHR VS OHV
N/A

Study Design

Study Type:
Interventional
Anticipated Enrollment :
54 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Evaluation of a Hysteroscopic Method With Vaporization in the Hysteroscopic Treatment of Submucosal Uterine Fibroids
Actual Study Start Date :
Sep 17, 2021
Anticipated Primary Completion Date :
Nov 17, 2023
Anticipated Study Completion Date :
May 17, 2024

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: OHR System

Use of the OHR system to perform an operative hysteroscopy by resection of the fibroid.

Procedure: OHR VS OHV
Control group : use of the OHR system to perform an Operative Hysteroscopy by Resection of the fibroid. Experimental group : use of the OHV system to perform an Operative Hysteroscopy by Vaporization of the fibroid.

Experimental: OHV System

Use of the OHV system to perform an operative hysteroscopy by vaporization of the fibroid.

Procedure: OHR VS OHV
Control group : use of the OHR system to perform an Operative Hysteroscopy by Resection of the fibroid. Experimental group : use of the OHV system to perform an Operative Hysteroscopy by Vaporization of the fibroid.

Outcome Measures

Primary Outcome Measures

  1. Operative time [Baseline]

    Operative time expressed in minutes

Secondary Outcome Measures

  1. The amount of distention fluid used during operative hysteroscopy [Baseline]

    Measured by collection of the distention fluid pockets at the end of the procedure

  2. Resection time [Baseline]

    Time estimated in cm3/min based on ultrasound measurement of the volume of the myoma involved in the resection preoperatively and postoperatively, related to the operative time

  3. Complication rate during operative hysteroscopy [Baseline]

    Cervical tear rate and Rate of uterine perforations

  4. The rate of discontinuation of the operative hysteroscopy before complete resection [Baseline]

    Rate of discontinuation because of uterine perforations, operative time greater than 60 minutes, quantity of distension fluid greater than 9 liters, deficit of distension fluid greater than 1 liter, per operative haemorrhage

  5. The rate of postoperative synechiae in patients of childbearing age. [between 6 and 8 weeks after the operation]

    Rate of postoperative synechiae diagnosed at follow-up hysteroscopy in patients of childbearing age.

  6. Operative pain [Baseline]

    Operative pain evaluated by a visual analog scale (0-100mm). If the patient has a score of 0, it means that he/she has no pain. The higher the value, the more intense the pain.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
Female
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Patient at least 18 years old.

  • Non-pregnant patient

  • A patient who had an ultrasound confirming the presence of a uterine fibroid to be treated less than 6 cm.

  • Patient who had a diagnostic hysteroscopy confirming the presence of a uterine fibroid to be treated of type 0, 1 or 2 according to the FIGO classification.

  • Patient presenting an indication for intra uterine fibroid resection (bleeding, fertility problems) by operative hysteroscopy.

  • Patient having agreed to participate in the study and having signed an informed consent.

Exclusion Criteria:
  • Minor patient

  • Patient not affiliated to a social security system

  • Persons benefiting from special protection: by virtue of articles L1121-5 to L1121-8 of the Public Health Code: pregnant or breast-feeding women, minors, adults under guardianship or curatorship, persons deprived of liberty.

  • Patient refusing to sign the consent or unable to receive the information necessary to give informed consent.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Assistance Publique Hôpitaux Marseille Marseille Bouches-du-Rhone France 13354

Sponsors and Collaborators

  • Assistance Publique Hopitaux De Marseille

Investigators

  • Study Director: François CREMIEUX, Director, AP-HM

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Assistance Publique Hopitaux De Marseille
ClinicalTrials.gov Identifier:
NCT05078307
Other Study ID Numbers:
  • 2021-09
  • IDRCB
First Posted:
Oct 14, 2021
Last Update Posted:
May 26, 2022
Last Verified:
May 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of May 26, 2022